Literature DB >> 12635133

Maspin expression in invasive breast cancer: association with other prognostic factors.

Syed K Mohsin1, Ming Zhang, Gary M Clark, D Craig Allred.   

Abstract

Maspin is a unique serine protease inhibitor with a molecular weight of 42 kDa. It has been shown to inhibit tumour cell motility and invasion in cell culture, and tumour growth and metastasis in animal models. There is very limited data on the prognostic utility of maspin in human breast cancer. We performed a preliminary study to assess the associations of maspin with other established prognostic factors in invasive breast cancer (IBC). 1068 paraffin-embedded IBCs were immunohistochemically stained with a monoclonal antibody to maspin. A nuclear signal was present in 96% and a cytoplasmic signal in 35% of the cases. Nuclear staining was related to oestrogen (ER) and progesterone receptor (PR) positivity (p < 0.0001), but not to S-phase fraction (SPF) or ploidy. Cytoplasmic staining was related to ER and PR negativity (p < 0.0001), high SPF (p < 0.0001), and aneuploidy (p = 0.003). Thus, maspin nuclear staining was significantly associated with good prognostic factors, while cytoplasmic staining was associated with poor prognostic markers. These findings suggest that the presence of maspin in two different compartments of the cell may have different biological and clinical implications. Additional studies are needed to evaluate further this expression profile of maspin in breast cancer. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12635133     DOI: 10.1002/path.1319

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  30 in total

1.  Aberrant methylation of the maspin promoter is an early event in human breast cancer.

Authors:  Bernard W Futscher; Megan M O'Meara; Christina J Kim; Margaret A Rennels; Di Lu; Lynn M Gruman; Richard E B Seftor; Mary J C Hendrix; Frederick E Domann
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

2.  Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer.

Authors:  Efthimia Tsoli; Petros K Tsantoulis; Alexandros Papalambros; Branko Perunovic; David England; David A Rawlands; Gary M Reynolds; Dimitrios Vlachodimitropoulos; Susan L Morgan; Chara A Spiliopoulou; Thanos Athanasiou; Vassilis G Gorgoulis
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

Review 3.  The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin.

Authors:  Margarida M Bernardo; Sijana H Dzinic; Maria J Matta; Ivory Dean; Lina Saker; Shijie Sheng
Journal:  J Cell Biochem       Date:  2017-03-21       Impact factor: 4.429

4.  Maspin Gene Expression in Invasive Ductal Carcinoma of Breast.

Authors:  Shahriar Dabiri; Mohammadmehdi Moeini Aghtaei; Jahanbano Shahryari; Manzume Shamis Meymandi; Sahar Amirpour-Rostami; Reza Foutohi Ardekani
Journal:  Iran J Pathol       Date:  2016

5.  Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer.

Authors:  Ke-Feng Lei; Bing-Ya Liu; Xiao-Long Jin; Yan Guo; Min Ye; Zheng-Gang Zhu
Journal:  Exp Ther Med       Date:  2012-03-30       Impact factor: 2.447

6.  Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy.

Authors:  Paulette Mhawech-Fauceglia; Pavel Dulguerov; Amy Beck; Marta Bonet; Abdelkarim S Allal
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

7.  Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors.

Authors:  Haydee Lara; Yuhua Wang; Adriana S Beltran; Karla Juárez-Moreno; Xinni Yuan; Sumie Kato; Andrea V Leisewitz; Mauricio Cuello Fredes; Alexei F Licea; Denise C Connolly; Leaf Huang; Pilar Blancafort
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

8.  Clinicopathological significance of maspin expression in breast cancer.

Authors:  Mi Ja Lee; Chae Hong Suh; Zhu-Hu Li
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

9.  Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer.

Authors:  Mario W Kramer; Sandra Waalkes; Jörg Hennenlotter; Jürgen Serth; Arnulf Stenzl; Markus A Kuczyk; Axel S Merseburger
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

10.  Downregulation of BCSG1 may correlate with better outcome of neoadjuvant chemotherapy for triple-negative breast cancer.

Authors:  Jinsong He; Weicai Chen; Huisheng Wu; Min Wang; Yuan Wang; Xiaojia She; Shufen Song; Hong Guan; Xianming Wang
Journal:  Oncol Lett       Date:  2012-09-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.